Interpace Biosciences (OTCMKTS:IDXG) Shares Up 351.4% – What’s Next?

Interpace Biosciences, Inc. (OTCMKTS:IDXG)’s share price was up 351.4% during trading on Friday. The company traded as high as $6.4250 and last traded at $6.41. Approximately 4,734 shares traded hands during mid-day trading, a decline of 34% from the average daily volume of 7,196 shares. The stock had previously closed at $1.42.

Interpace Biosciences Stock Up 351.4%

The stock has a market capitalization of $28.40 million, a P/E ratio of 80.12 and a beta of 0.61. The business has a fifty day moving average price of $1.61 and a 200-day moving average price of $1.73.

Interpace Biosciences (OTCMKTS:IDXG) last released its quarterly earnings data on Monday, August 10th. The business services provider reported $0.01 EPS for the quarter. Interpace Biosciences had a return on equity of 145.40% and a net margin of 67.64%.The company had revenue of $9.13 million for the quarter.

About Interpace Biosciences

Interpace Biosciences, Inc is a molecular diagnostics company focused on providing testing and pathology services that support the diagnosis and management of cancer and other complex diseases. The company’s tests are designed to help physicians assess disease risk, improve diagnostic confidence and guide treatment decisions.

Its portfolio has included molecular tests for thyroid nodules, pancreatic cysts and gastrointestinal conditions. Key offerings include ThyGeNEXT and ThyraMIR for evaluating thyroid nodules, as well as PancraGEN and PanDNA for assessing pancreatic cysts.